Korro Bio, Inc.

NASDAQ•KRRO

CEO: Mr. Nessan Bermingham Ph.D.

セクター: Healthcare

業種: Biotechnology

上場日: 2019-10-03

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

連絡先情報

One Kendall Square, Building 600-700 Suite 6-401, Cambridge, MA, 02139, United States

617-468-1999

www.korrobio.com

時価総額

$103.12M

PER (TTM)

-1.2

17.8

配当利回り

52週高値

$55.89

52週安値

$5.20

52週レンジ

11%

順位59Top 87.6%

2.2

F-Score

改良版 Piotroski 分析

8年ファンダメンタル

弱い • 2.2 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2018-2025

財務ダッシュボード

Q3 2025 データ

売上高

$1.09M+0.00%

直近4四半期の推移

EPS

-$1.92-15.04%

直近4四半期の推移

フリーCF

-$17.35M-17.26%

直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Collaboration Revenue Recognized Nine months collaboration revenue reached $5.1M, compared to zero recognized in the prior nine months period.

R&D Expenses Increased Research and development expenses rose $7.9M to $54.6M for nine months, funding pipeline advancement.

KRRO-121 Candidate Nominated Nominated KRRO-121 for UCD/HE treatment; planning first-in-human regulatory filing in second half 2026.

Cash Runway Extended Cash, cash equivalents, and marketable securities totaled $102.5M, funding operations into second half 2027.

リスク要因

KRRO-110 Program Pivoting KRRO-110 failed to meet AATD protein goals; pivoting delivery method, which may cause development delays.

Increased Net Loss Nine months net loss widened to $67.2M from $62.4M; requires substantial future capital infusion.

Workforce Reductions Impact Implemented two workforce reductions (May and November 2025); future expansion efforts face integration challenges.

Novo Nordisk Collaboration Paused Novo Nordisk collaboration paused for 12 months starting November 2025, suspending expected revenue recognition.

見通し

KRRO-121 Clinical Trial Filing Plan to submit regulatory filing for KRRO-121 first-in-human trial during the second half of 2026.

AATD Candidate Nomination Prioritizing GalNAc-conjugated AATD program; expect to nominate a development candidate during 2026.

Continued High R&D Spending Expect substantial increase in R&D expenses to advance pipeline through clinical development stages.

Pursuing Additional Financing Will pursue additional cash resources through public or private equity offerings, collaborations, or debt financings.

同業比較

売上高 (TTM)

AMRN

$183.87M

-19.6%

CLLS

$75.27M

+158.9%

ADCT

$75.21M

+6.4%

粗利益率 (最新四半期)

AMRN

119.2%

+7.3pp

KRRO

100.0%

+0.0pp

CLLS

93.3%

+10.5pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
RAPT	$959.51M	-14.8	-61.8%	1.6%
ANNX	$649.40M	-3.9	-92.3%	11.8%
DBVT	$528.19M	-3.3	-295.2%	14.5%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

-21.7%

成長鈍化

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年3月17日

EPS:-$1.93

売上高:$425.00K

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし